In this article by Manufacturing Chemist, Thierry Van Nieuwenhove, CEO of Quotient Sciences, discusses the Merck & AstraZeneca UK investment pull back.
With Big Pharma pausing UK investments, contract development and manufacturing organisations (CDMOs) are positioning their agility and technical depth to fill the gap. Quotient Sciences CEO Thierry Van Nieuwenhove says clinical trial bottlenecks have been a drag, but notes approvals are now moving faster—around 41 days for initial MHRA reviews—strengthening the case for UK-based development and manufacturing.
Continue reading the full article on Manufacturing Chemist.